SHLT SHL Telemedicine
- 5.520
- -0.070-1.25%
SHL Telemedicine News
Strong Week for SHL Telemedicine (VTX:SHLTN) Shareholders Doesn't Alleviate Pain of Three-year Loss
Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Tuesday as Investors Await Fresh Catalysts
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was marginally up by 0.01% and the actively traded Invesco QQQ Trust (QQQ) was 0.1% lower as markets were mixed in Tuesday's premarke
SHL Telemedicine Expands Offering in Israel With Groundbreaking At-home Biomarker Blood Test
Users in Israel will be able for the first time in the world to perform an at-home Biomarker blood test guided by SHL's medical team, following ECG tests using The SmartHeart for Rapid Heart Attack
SHL Telemedicine Announces Official Launch of SmartHeart D2C Membership in the US Following Successful Soft Launch
A revolutionary at-home 12-lead ECG service with 24/7 cardiologist review and telehealth service now fully available in the US. SHL Telemedicine Ltd. (NASDAQ:SHLT, SIX: SHLTN, )) ("SHL" or the
SHL Telemedicine Shareholders Approve Key Policy
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
GainersCyclacel Pharmaceuticals (NASDAQ:CYCC) stock moved upwards by 50.0% to $2.04 during Tuesday's pre-market session. The company's market cap stands at $2.6 million. GeneDx Hldgs (NASDAQ:WGS) shar
When Will SHL Telemedicine Ltd. (VTX:SHLTN) Breakeven?
SHL Telemedicine Full Year 2023 Earnings: US$0.43 Loss per Share (Vs US$0.005 Loss in FY 2022)
SHL Telemedicine Reports Revenue Growth Amid Expansion
SHL Telemedicine FY Net Loss $(6.9)M Vs. $(0.4)M YoY
SHL Telemedicine FY Net Loss $(6.9)M Vs. $(0.4)M YoY
SHL Telemedicine FY Sales $57.1M Up From $55.4M YoY
SHL Telemedicine FY Sales $57.1M Up From $55.4M YoY
Press Release: SHL Announces Full-Year 2023 Results - Stable Revenue Growth Alongside Groundbreaking Clinical Milestones
In 2023, SHL Telemedicine achieved key highlights, underscoring its global market strength.
SHL Telemedicine Reports Wider FY23 Attributable Loss
SHL Telemedicine (SHLTN.SW) on Wednesday reported a wider loss for 2023, while revenue fell year over year. Net loss attributable to equity holders for the 12 months ended Dec. 31, 2023, was $7.1 mill
12 Health Care Stocks Moving In Tuesday's After-Market Session
GainersClene (NASDAQ:CLNN) shares moved upwards by 54.9% to $0.48 during Tuesday's after-market session. The company's market cap stands at $61.6 million. Talphera (NASDAQ:TLPH) shares moved upwards b
Imperial College London Study Shows Groundbreaking Final Results for SHL Telemedicine's SmartHeart in Post-ACS Patient Care
Groundbreaking Study reveals a 76% drop in hospital readmissions and a 41% decrease in Emergency Department visits, underscoring SHL and SmartHeart's pivotal role in remote cardiac care SHL Telemedicine Ltd.
12 Health Care Stocks Moving In Monday's Pre-Market Session
GainersLongeveron (NASDAQ:LGVN) shares moved upwards by 75.0% to $3.85 during Monday's pre-market session. The market value of their outstanding shares is at $9.6 million. PetVivo Hldgs (NASDAQ:PETV)
SHL's SmartHeart ECG Technology Showcases Potential in US Army's Largest Field Experiment
SHL Telemedicine Ltd. (NASDAQ:SHLT, SIX: SHLTN, ))))) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions is pleased to share that in a remarkable display of innovation and operational excellence, the Company's SmartHeart, portable 12-lead ECG technology showcased its unparalleled capabilities and successfully participated in Project Convergence – Capstone 4 (PC-C4), the largest, two-phase, "in-the-dirt" experiment to date that includes enduring objectives and learning demands evolving from the Project Convergence campaign of persistent experimentation. One key event during the experiment was a comprehensive multi-day army medical experiment held at Fort Irwin's National Training Center in the Mojave Desert amidst the challenging terrains of California's Tiefort Mountains.
SHL Telemedicine: Invitation to Conference Call Presenting Annual Results 2023
TEL AVIV, Israel & ZURICH & NEW YORK--(BUSINESS WIRE)--$SHLT--SHL Telemedicine Ltd. (SIX Swiss Exchange: SHLTN; NASDAQ: SHLT) ("SHL" or the "Company"), a leading provider and developer of advanced per
SHL Telemedicine Announces Shareholders Meeting
SHL Telemedicine Initiated at Buy by Litchfield Hills
SHL Telemedicine Initiated at Buy by Litchfield Hills
Analysis
Price Target
No Data
